All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On 7 November 2018, the US Food and Drug Administration (FDA) granted Fast Track Designation to selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies and are not eligible for high-dose chemotherapy with stem cell rescue or CAR-T therapy. Selinexor is a novel, selective inhibitor of nuclear export (SINE) compound, which inhibits exportin 1 (XPO1), a karyopherin protein, that facilitates the nuclear export of tumor suppressor proteins.1
The efficacy of single-agent selinexor is being examined in a phase IIb study (SADAL) in patients with relapsed or refractory (R/R) DLBCL after ≥ 2 prior regimens. In an interview with the Lymphoma Hub, John Kuruvilla from the Princess Margaret Cancer Centre, Toronto, CA, talks about the design of the phase IIb study. Briefly, patients were randomized to receive 60 mg or 100 mg of selinexor twice weekly (8 doses) per 28-day cycle. Additionally, patients were grouped by the subtype of their DLBCL (GCB or non-GCB). The primary and secondary endpoints were to determine the objective response rate (ORR), and duration of response respectively.
Data from this study presented at the 23rd Congress of the European Association of Hematology demonstrated that monotherapy with selinexor exhibits anti-cancer activity in R/R DLBCL patients including those with GCB subtype. In addition, dosing at 60 mg twice weekly was tolerated better than 100 mg twice weekly, with fewer interruptions to dosing due to toxicity. Moreover, durable objective responses were achieved with selinexor, which may be “associated with clinical benefit.”2
According to the manufacturers, the Fast Track Designation granted to selinexor for patients with R/R DLBCL “underscores the great unmet medical need for this aggressive form of lymphoma.”1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox